Entity
Isomorphic Labs
Isomorphic Labs, Alphabet's AI drug discovery spinoff, is reportedly raising new funding at a valuation of $40-50 billion, according to Bloomberg, highlighting surging capital interest in AI-driven biotech.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Overview
Isomorphic Labs Ltd., an Alphabet Inc. spinoff focused on accelerating drug discovery using AI, is reportedly raising a new funding round at a valuation of between $40 billion and $50 billion (SiliconANGLE, October 8, citing Bloomberg).
## Key Details
- The report, from Bloomberg, did not specify the size of the funding deal (SiliconANGLE, October 8).
- Isomorphic Labs was spun off from Alphabet and works on AI-driven drug discovery (SiliconANGLE, October 8).
## Why It Matters
A valuation in the $40–50 billion range would mark Isomorphic Labs as one of the most highly valued AI-driven biotech companies, underscoring the scale of capital flowing into AI drug discovery. This is a storyline likely to recur as the funding round closes and as competitors in AI-for-biotech seek similar valuations.